The Evaluation of oxidative stress, 3-nitrotyrosine, and HMGB-1 levels in patients with Wet Type Age-Related Macular Degeneration
Oxidative stress, 3-NT, and HMGB-1 levels in patients with wAMD
Abstract
Abstract
Background: This study aims to compare serum HMGB-1, 3-nitrotyrosine (3-NT), TAS, TOS, and OSI levels in Wet-type Age-Related Macular Degeneration (wAMD) patients and healthy controls to determine the correlation of these parameters with each other.
Methods: Thirty patients with Wet-type Age-Related Macular Degeneration (wAMD) and 27 healthy adults, as controls were enrolled in the study. We determined the TAS and TOS levels in serum samples of both groups using commercial kits on a microplate reader. Serum HMGB-1 and 3-NT levels were measured with the enzyme-linked immunosorbent assay method.
Results: HMGB-1 levels were significantly higher in the patient group (137.51 pg / mL, p=0.001), while there was no difference between the two groups in serum 3-NT levels (p=0.428). A statistically significant difference found in the levels of TOS and OSI (p=0.001 and p=0.045, respectively) between the patients and controls, however, no significant difference was observed between the groups in terms of TAS levels (p=0.228).
Conclusions: Oxidative stress and HMGB-1 levels were increased in wAMD patients and enhanced oxidative stress may be associated with increased tissue necrosis and inflammation. Thus administration of antioxidant treatment in addition to routine therapy should be considered in wAMD.
References
1. Evans Kauppinen A. Introduction to the multi-author review on macular degeneration. Cell Mol Life Sci. 2020;77(5):779-780.
2. Ferris FL 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, Sadda SR, and Beckman Initiative for Macular Research Classification Committee. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844–51.
3. Kauppinen A, Paterno JJ, Blasiak J, Salminen A, Kaarniranta K. Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci. 2016;73(9):1765-1786.
4. Tsung A, Tohme S, Billiar TR. High-mobility group box-1 in sterile inflammation. J Intern Med. 2014; 276: 425–443.
5. Fiuza C, Bustin M, Talwar S, et al. Inflammation-promoting activity of HMGB-1 on human microvascular endothelial cells. Blood. 2003;101(7): 2652–2660.
6. Hanus J, Anderson C, Sarraf D, Ma J, Wang S. Retinal pigment epithelial cell necroptosis in response to sodium iodate. Cell Death Discov. 2016;2:16054.
7.Sun S, Cai B, Li Y, Su W, Zhao X, Gong B, Li Z, Zhang X, Wu Y, Chen C, Tsang SH, Yang J, Li X. HMGB-1 and Caveolin-1 related to RPE cell senescence in age-related macular degeneration. Aging (Albany NY). 2019; 11(13): 4323-4337.
8. Murdaugh LS, Wang Z, Del Priore LV, Dillon J, Gaillard ER. Age-related accumulation of 3-nitrotyrosine and nitro-A2E in human Bruch's membrane. Exp Eye Res. 2010;90(5):564-71.
9. Radi R. Protein tyrosine nitration: biochemical mechanisms and structural basis of functional effects. Acc Chem Res. 2013 Feb 19;46(2):550-9.
10. Kaya Erdogan H, Bulur I, Kocaturk E, Yildiz B, Saracoglu ZN, Alatas O. The role of oxidative stress in early-onset androgenetic alopecia.
J Cosmet Dermatol. 2017;16(4):527-530.
11. Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004;37(4):277-85.
12. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38(12):1103-11.
13. Datta S, Cano M, Ebrahimi K, Wang L, Handa JT. The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD. Prog Retin Eye Res. 2017;60:201-218.
14 . Hanus J, Anderson C, Wang S. RPE necroptosis in response to oxidative stress and in AMD. Ageing Res Rev. 2015;24(Pt B):286-98.
15. Qin S, Rodrigues GA. Progress and perspectives on the role of RPE cell inflammatory responses in the development of age-related macular degeneration. J Inflamm Res. 2008;1:49–65.
16. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB-1 by necrotic cells triggers inflammation. Nature. 2002;418:191–195.
17. Hanus J, Zhang H, Wang Z, Liu Q, Zhou Q, Wang S. Induction of necrotic cell death by oxidative stress in retinal pigment epithelial cells. Cell Death Dis. 2013;4:e965.
18. Goodwin G.H, Sanders C, Johns EW. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur. J. Biochem. 1973;38:14–19.
19. Malarkey C.S., Churchill M.E.A. The high mobility group box: The ultimate utility player of a cell. Trends Biochem. Sci. 2012;37:553–562.
20. Shen X, Li WQ. High-mobility group box 1 protein and its role in severe acute pancreatitis. World J Gastroenterol. 2015;21(5):1424-35.
21. Kikuchi H, Yagi H, Hasegawa H, Ishii Y, Okabayashi K, Tsuruta M, Hoshino G, Takayanagi A, Kitagawa Y. Therapeutic potential of transgenic mesenchymal stem cells engineered to mediate anti-high mobility group box 1 activity: targeting of colon cancer. J Surg Res. 2014;190:134–143.
22.van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, Hautvast P, Buurman WA, Griffioen AW. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene. 2013;32:363–374.
23. Gnanasekar M, Kalyanasundaram R, Zheng G, Chen A, Bosland MC, Kajdacsy-Balla A. HMGB-1: A Promising Therapeutic Target for Prostate Cancer. Prostate Cancer. 2013;2013:157103.
24. Yang S, Xu L, Yang T, Wang F. High-mobility group box-1 and its role in angiogenesis. J Leukoc Biol. 2014;95:563–574.
25. Sakamoto K, Mizuta A, Fujimura K, Kurauchi Y, Mori A, Nakahara T, Ishii K. High-mobility group Box-1 is involved in NMDA-induced retinal injury the in rat retina. Exp Eye Res. 2015;137:63-70.
26. Chang YC, Lin CW, Hsieh MC, Wu HJ, Wu WS, Wu WC, Kao YH. High mobility group B1 up-regulates angiogenic and fibrogenic factors in human retinal pigment epithelial ARPE-19 cells. Cell Signal. 2017;40:248-257.
27. Watanabe T, Keino H, Sato Y, Kudo A, Kawakami H, Okada AA.High mobility group box protein-1 in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2009;50(5):2283-90.
28. Murakami Y, Ikeda Y, Nakatake S, Tachibana T, Fujiwara K, Yoshida N, Notomi S, Nakao S, Hisatomi T, Miller JW, Vavvas DG, Sonoda KH, Ishibashi T. Necrotic enlargement of cone photoreceptor cells and the release of high-mobility group box-1 in retinitis pigmentosa. Cell Death Discov. 2015;1:15058.
29.Liu Q, Li J, Cheng R, Chen Y, Lee K, Hu Y, Yi J, Liu Z, Ma JX. Nitrosative stress plays an important role in Wnt pathway activation in diabetic retinopathy. Antioxid Redox Signal. 2013;18(10):1141-53.
30. Thomson L. 3-nitrotyrosine modified proteins in atherosclerosis. Dis Markers. 2015;2015:708282.
31. Bandookwala M, Sengupta P. 3-Nitrotyrosine: a versatile oxidative stress biomarker for major neurodegenerative diseases. Int J Neurosci. 2020:1-16.
32. Nitrotyrosine level was associated with mortality in patients with acute kidney injury. Qian J, You H, Zhu Q, Ma S, Zhou Y, Zheng Y, Liu J, Kuang D, Gu Y, Hao C, Ding F. PLoS One. 2013;8(11):e79962.
33. Khan F, Siddiqui AA, Ali R. Measurement and significance of 3-nitrotyrosine in systemic lupus erythematosus. Scand J Immunol. 2006;64(5):507-14.
34. Wang B, Liu Y, Xu Q, Wang J. [Investigation to the levels of 3-nitrotyrosine and their correlation factors in type 2 diabetic patients]. Wei Sheng Yan Jiu. 2009;38(4):433-6.
35. Kanan Y, Khan M, Lorenc VE, Long D, Chadha R, Sciamanna J, Green K, Campochiaro PA. Metipranolol promotes structure and function of retinal photoreceptors in the rd10 mouse model of human retinitis pigmentosa. J Neurochem. 2019;148(2):307-318.
36. Jafri AJA, Agarwal R, Iezhitsa I, Agarwal P, Spasov A, Ozerov A, Ismail NM. Protective effect of magnesium acetyltaurate and taurine against NMDA-induced retinal damage involves reduced nitrosative stress. Mol Vis. 2018;24:495-508.
37. Wang Z, Paik DC, Del Priore LV, Burch RL, Gaillard ER. Nitrite-modified extracellular matrix proteins deleteriously affect retinal pigment epithelial cell function and viability: a comparison study with nonenzymatic glycation mechanisms. Curr Eye Res. 2005;30(8):691-702.
38. Lymperaki E, Makedou K, Iliadis S, Vagdatli E. Effects of acute cigarette smoking on total blood count and markers of oxidative stress in active and passive smokers. Hippokratia. 2015;19(4):293-7.
39. Karademirci M, Kutlu R, Kilinc I. Relationship between smoking and total antioxidant status, total oxidant status, oxidative stress index, vit C, vit E. Clin Respir J. 2018;12(6):2006-2012.
40. Icel E, Icel A, Uçak T, Karakurt Y, Elpeze B, Keskin Çimen F, Süleyman H. The effects of lycopene on alloxan induced diabetic optic neuropathy. Cutan Ocul Toxicol. 2019;38(1):88-92.
41. Oruc Y, Keser S, Yusufoglu E, Celik F, Sahin İ, Yardim M, Aydin S. Decorin, Tenascin C, Total Antioxidant, and Total Oxidant Level Changes in Patients with Pseudoexfoliation Syndrome. J Ophthalmol. 2018;2018:7459496.
42. Altinisik M, Koytak A, Elbay A, Toklu E, Sezer T, Kocyigit A. Oxidant-Antioxidant Balance in the Aqueous Humor of Patients with Retinal Vein Occlusion. Semin Ophthalmol. 2018;33(5):675-682.
43. Elbay A, Ozer OF, Akkan JCU, Celik U, Kutlutürk I, Koytak A, Ozdemir H. Comparison of serum thiol-disulphide homeostasis and total antioxidant-oxidant levels between exudative age-related macular degeneration patients and healthy subjects. Int Ophthalmol. 2017;37(5):1095-1101.
Copyright (c) 2021 Kürşad Ramazan Zor, İsmail Sarı, Gamze Yıldırım, İnayet Güntürk, Erkut Küçük, Serpil Erşan, Gönül Şeyda Seydel
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.